SCHEMBL6770537

SCHEMBL6770537

NC(=O)c1cccc2c1c1c(O)cc(-c3ccccc3)cc1n2Cc1cccc(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.41
POLB P06746 2/20 0.41
IDO1 P14902 1/20 0.41
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
FABP4 P15090 1/20 0.40
ICMT O60725 1/20 0.40
PLA2G2A P14555 3/20 0.40
F10 P00742 1/20 0.40
PLA2G1B P04054 1/20 0.39
FEN1 P39748 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
PLA2G10 O15496 1/20 0.38
MAPK8 P45983 1/20 0.38
CDC7 O00311 1/20 0.38
ROCK2 O75116 1/20 0.38
MAP4K4 O95819 1/20 0.38
PIM1 P11309 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6770631 0.91 PLA2G2A (0.46) POLBFABP4PLA2G2AF10PLA2G1B
SCHEMBL6694433 0.91 PLA2G2A (0.46) POLBPLA2G2APLA2G1BPLA2G10SRC
SCHEMBL6772770 0.91 PLA2G2A (0.41) POLBIDO1LMNAGLAICMT
SCHEMBL6774933 0.88 PLA2G2A (0.42) PLA2G2AF10PLA2G1BPLA2G10
SCHEMBL6691129 0.88 F10 (0.46) FABP3POLBIDO1LMNAGLA
SCHEMBL6773052 0.88 PLA2G2A (0.50) LMNAPLA2G2AF10PLA2G1B
SCHEMBL6774185 0.88 TP53 (0.47) ICMTPLA2G2AF10PLA2G1B
SCHEMBL6775875 0.88 PLA2G2A (0.40) PLA2G2AF10PLA2G1BFEN1PLA2G10
SCHEMBL6776400 0.87 MAPT (0.45) POLBLMNAFABP4ICMTF10
SCHEMBL6897173 0.87 MAPT (0.44) FABP3POLBIDO1LMNAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed